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Abstract: The relatively rapid development of microbial resistance after the entry of every 
new antimicrobial into the marketplace necessitates a constant supply of new agents to maintain 
effective pharmacotherapy. Despite extensive efforts to identify novel lead compounds from 
molecular targets, only the peptide deformylase inhibitors (PDIs) have shown any real promise, 
with some advancing to phase I human trials. Bacterial peptide deformylase, which catalyzes the 
removal of the N-formyl group from N-terminal methionine following translation, is essential 
for bacterial protein synthesis, growth, and survival. The majority of PDIs are pseudopeptide 
hydroxamic acids and two of these (IV BB-83698 and oral NVP LBM-415) entered phase I 
human trials. However, agents to the present have suffered from major potential liabilities. Their 
in vitro activity has been limited to gram-positive aerobes and some anaerobes and has been 
quite modest against the majority of such species (MIC90 values ranging from 1–8 mg/L). They 
have exerted bacteriostatic, not bacteriocidal, activity, thus reducing their potential usefulness in 
the management of serious infections in the immunocompromised. The relative ease with which 
microorganisms have been able to develop resistance and the multiple available mechanisms 
of resistance (mutations in fmt, defB, folD genes; AcrAB/TolC efﬂ  ux pump; overexpression 
of peptide deformylase) are worrisome. These could portend a short timespan of efﬁ  cacy after 
marketing. Despite these current liabilities, further pursuit of more potent and broader spectrum 
PDIs which are less susceptible to bacterial mechanisms of resistance is still warranted.
Keywords: peptide deformylase, peptide deformylase inhibitors, actinonin, LBM-415, 
BB-83698, BB-3497
Natural products have played pivotal roles in the development of antimicrobials since 
the early years of the twentieth century. However, the relatively rapid onset of micro-
bial resistance with every new antimicrobial introduced into the marketplace requires 
a constant supply of new agents for effective therapy of infectious diseases. Table 1 
illustrates natural product-derived antimicrobial compounds undergoing investigation 
(including natural product templates and new templates present in recently-discovered 
lead antimicrobials) [Butler and Buss 2006]. Despite extensive efforts to identify novel 
lead compounds from molecular targets, only the peptide deformylase inhibitors (PDIs) 
are currently in clinical trials.
Bacterial peptide deformylase (EC 3.5.1.31) is an enzyme responsible for cata-
lyzing the removal of the N-formyl group from N-terminal methionine following 
translation. This enzyme is encoded by the def gene, which is present in all pathogenic 
bacteria, including Mycoplasma and Chlamydia species, and which does not share a 
functionally equivalent gene in mammalian cells. The def gene is an essential gene for 
bacterial growth and survival (this has been validated for Streptococcus pneumoniae 
and Escherichia coli) [Mazel et al 1994; Chan et al 2003]. The enzyme contains 
three highly conserved catalytic domains and belongs to the matrix metallo-protease 
(MMP) family of enzymes. Blockade of bacterial peptide deformylase produces Therapeutics and Clinical Risk Management 2007:3(4) 514
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inhibition of protein synthesis (similar to the mechanism of 
the tetracyclines, macrolides, streptogramins, lincosamides, 
and chloramphenicol).
The only naturally-occurring PDIs are actinonin and 
macrolactin N [Chen et al 2000; Yoo et al 2006]. Although 
actinonin is too weak an inhibitor to use clinically, it did form 
the framework for the synthesis, puriﬁ  cation, and evaluation 
of more potent PDIs [Chen et al 2000].
Individual papers have reviewed the discoveries of 
BB-3497 [Clements et al 2001], VRC 3852 [Hackbarth et al 
2002], VRC 3375 [Jain et al 2003; Chen et al 2004], Ro 
66-0376 and Ro 66-6976 [Apfel et al 2000], and PDF-611 
(LBK611) [Yoo et al 2006]. Table 2 outlines the peptide 
deformylase inhibitors of greatest potential. The pseudo-
peptidic hydroxamic acids (or N-formyl-N-hydroxylamines) 
constitute the largest group and two of these compounds were 
investigated for some time in human clinical trials (intrave-
nous BB-83698 and oral LBM-415). The chemical structures 
of these latter two PDIs are illustrated in the Figure 1.
Chemistry
Peptide deformylase inhibitors are selective for bacterial 
enzyme and exhibit activity against similar mammalian 
(including human) enzymes only at extremely high con-
centrations unlikely to be achievable in vivo. For example, 
BB-81384 inhibits the peptide deformylase (Ni complex) 
of Streptococcus pneumoniae, Haemophilus inﬂ  uenzae, 
E. coli, and Staphylococcus aureus with IC50 values of 9, 
11, 60, and 300 nM, respectively [Gross et al 2004], where 
IC50 refers to the concentration inhibiting enzyme activity 
by 50 percent. Corresponding IC50 values for the human 
metalloenzymes collagenase (MMP-1), gelatinase (MMP-2) 
and angiotensin converting enzyme (ACE) were 10000, 
60000, and 5000 nM, respectively [Gross et al 2004]. In 
the development of VRC 3852, 20/21 related compounds 
(95%) exhibited IC50 values of 100 nM or less for E. coli 
Table 1 Natural product-derived antimicrobial compounds under investigationa
Name (synonym)  Class (lead compound)  Developer 
NVP LBM 415 (NVP PDF 713)  Peptide deformylase inhibitor (actinonin)  Novartis
Rifalazil (ABI-1648, KRM-1648)  Ansamycin (rifamycin B)  ActivBiotics
Ceftobripole medocaril (BAL-5788)  β-lactam-cephalosporin  Basilea and J & J
PPI-0903 (TAK-599)  β-lactam-cephalosporin Cerexa
RWJ-442831  β-lactam-cephalosporin  J & J
CS-023 (R1558)  β-lactam-cephalosporin Roche/Sankyo
Tebipenem pivoxil (ME1211)  β-lactam-carbapenem  Meiji Seika Kaisha
ME1036 (CP5069)  β-lactam-carbapenem  Meiji Seika Kaisha
Faropenem daloxate  β-lactam-penem Replidyne
Dalbavancin glycopeptide  (A40926)  Vicuron
Telavancin (TD-6424)  glycopeptide (vancomycin)  Theravance
Cethromycin  macrolide (erythromycin)  Advanced Life Sciences
EP-013420 macrolide  (erythromycin)  Enanta/Shionogi
Pleuromutilin derivative (565154)  new (pleuromutilin)  GlaxoSmithKline
Ramoplanin new  (ramoplanin)  Oscient
NXL103 (XRP2868)-RPR132552A and RPR202698  streptogramin  Novexel
PTK0796 tetracycline  Paratek
Tiacumicin B (PAR-101, OPT-80)  new (tiacumicin)  Par
a14/19 are derivates of known drugs. only NVP LBM-415, pleuromutilin derivative (565154), ramoplanin, and tiacumicin B are not related to drugs previously marketed for 
human use.
Table 2 Peptide deformylase inhibitors
A. Peptidic  Inhibitors
    I.    Thiol Class
    II.   Pseudopeptidic Hydroxamic Acid or N-formyl-N-Hydroxyl-
 amine  Class
          Actinonin
        BB-83698  (Vernalis,  formerly  British  Biotech)
        BB-3497  (Vernalis,  formerly  British  Biotech)
          VRC 3375
          VRC 3324
          VRC 4307
          VRC 4887 (NVP PDF 386)
        LBM-415 (NVP PDF 713) (VIC-104959) (Novartis, Vicuron)
        LBK-611  (PDF-611)  (Novartis)
    III.  Metalloprotease Inhibitors
        GMG001
          TAP I-O
B.    Non-Actinonin-Based, Non-Peptidic Inhibitors
      β-sulfonylhydroxamic acid
      β-sulﬁ  nylhydroxamic acid
       2 Bicyclic hydroxamic acids
      Macrocyclic  compoundTherapeutics and Clinical Risk Management 2007:3(4) 515
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peptide deformylase and 18/20 (90%) exhibited IC50 values 
of 75 nM or less for S. pneumoniae peptide deformylase. All 
21 compounds were very selective, with IC50 values for 
tested human metalloenzymes being 200000 nM or greater 
[Hackbarth et al 2002]. Two PDIs exhibited potent activity 
against the peptide deformylase of Mycobacterium bovis 
BCG: PDF-611 (IC50 of 69.5 nM) and BB-3497 (IC50 of 
24.9 nM) [Teo et al 2006].
The majority of PDIs are hydroxamic acid derivatives 
(Figure 1), in which the PDI coordinates with the active-site 
metal atom [Huo et al 1999; Clements et al 2001; Guilloteau 
et al 2002; Hackbarth et al 2002]. These data have been 
obtained during crystallography studies of enzyme-substrate 
complexes at resolutions of 2Å or less. Two PDIs produce 
time-dependent inhibition of peptide deformylase: actinonin 
and BB-3497 (including its 15-membered macrocyclic ring 
analogue) [Hu et al 2003, 2004; Van Aller et al 2005]. With 
these agents, binding to the enzyme occurs in two steps, 
wherein the initial encounter complex tightens into a ﬁ  nal 
encounter complex with an extremely slow rate of dissocia-
tion (half-life for dissociation 0.77 days [actinonin] and 
1.9 days [BB-3497]) [Van Aller et al 2005].
The effect of NVP LBM 415 on the proteomes of 
S. aureus and S. pneumoniae has been studied using two-
dimensional electrophoresis. During exposure to PDI, 
similar ﬁ  ndings were noted with both microorganisms. 
Many N-terminal formylated peptides/proteins were seen, 
their accumulation being time-dependent and the degree of 
accumulation differing for different peptides/proteins. Upon 
removal of PDI, these peptides/proteins underwent defor-
mylation in a time-dependent manner. However, if sub-MIC 
(minimum inhibitory concentration) concentrations of the 
PDI were maintained over time, high levels of formylated 
peptides/proteins were present for a longer period and this 
correlated with a prolonged post-antibiotic effect (PAE) in 
vitro [Wang et al 2006].
The PDIs may also work via stimulation of the innate 
immune system. The innate immune system uses the 
Figure 1 Chemical structures of the peptide deformylase inhibitors BB-83698 and NVP LBM-415.Therapeutics and Clinical Risk Management 2007:3(4) 516
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formylation of bacterial proteins as a target and profes-
sional phagocytes express receptors for bacterial-derived 
formylated peptides. Activation of formyl peptide receptors 
(FPR) mediates phagocyte (neutrophil) migration and release 
of free radicals and other antimicrobial substances from 
phagocytes. Theoretically, PDIs should enhance this response 
and, hence, innate immunity. This has been demonstrated 
with actinonin in animal models. In subtherapeutic doses, 
actinonin enhances the production and secretion of neutro-
phil-activating peptides that work via FPR [Fu et al 2003].
In vitro antibacterial activity
Peptide deformylase inhibitors are much less active against 
intact bacteria than predicted by their kinetics of inhibition 
of puriﬁ  ed enzyme, likely due to the barrier effects of the cell 
wall and outer membrane and the presence of active efﬂ  ux 
pump mechanisms [Apfel et al 2000].
These agents generally lack useful activity against 
Enterobacteriaceae and non-fermentative gram-negative 
bacilli [Jones and Rhomberg 2003]. However, BB-3497 was 
active against single isolates of E. coli, Enterobacter cloacae, 
and Klebsiella pneumoniae (MIC = 8 mg/L for each) [Cle-
ments et al 2001]. In addition, Ro 66-0376 and Ro 66-6976 
were active against one isolate of Stenotrophomonas malto-
philia (MIC < 0.25 mg/L and 4 mg/L, respectively) [Apfel 
et al 2000]. Structure-activity relationship studies with the 
VRC series of compounds suggest the feasibility of extending 
the spectrum of activity of the PDIs to include gram-negative 
microorganisms [Hackbarth et al 2003].
Tables 3 and 4 illustrate the in vitro antibacterial activi-
ties of the British Biotech (BB) and Vicuron/Novartis (NVP) 
series of PDIs, respectively [Wootton et al 2001; Wise et al 
2002; Bowker et al 2003; Jones and Rhomberg 2003; Roblin 
and Hammerschlag 2003; Credito et al 2004; Cynamon et al 
2004; Ednie et al 2004; Jones et al 2004; Loﬂ  and et al 2004; 
Bell et al 2005; Edelstein et al 2005; Fritsche et al 2005; Jones 
et al 2005; Snydman et al 2005; Waites et al 2005; Teo et al 
2006; Watters et al 2006].
Within a series of ﬁ  ve British Biotech compounds evalu-
ated for in vitro activity against C. pneumoniae (strains TW 
183, CT 815, CT 712), the activity was quite variable: for TW 
183 and CT815, MIC range of 0.5 to 2 mg/L and minimum 
lethal concentration (MLC) range of 0.5 to 4 mg/L and for 
CT 712, MIC range of 0.25 to 4 mg/L and MLC range of 
0.25 to 8 mg/L [Wise et al 2002].
NVP LBM-415 has demonstrated modest-moderate ac-
tivity against linezolid-resistant staphylococci (N = 6, MIC 
range of 0.25–2 mg/L), Streptococcus oralis (N = 1, MIC 
0.5 mg/L), E. faecalis (N = 3, MIC range of 2–4 mg/L), 
and E. faecium (N = 10, MIC range of 0.5–4 mg/L) [Jones 
et al 2004a]. It has also demonstrated a similar degree of 
activity against quinupristin/dalfopristin-resistant E. faecium 
(N = 6, MIC range of 1–2 mg/L) and staphylococci (N = 19, 
MIC range of 0.12–2 mg/L) [Jones et al 2004a]. Two PDIs 
exhibit reasonable in vitro activity against mycobacteria: 
PDF-611 (MIC90 = 0.25 mg/L vs. M. bovis BCG) and BB-
3497 (MIC90 = 0.5–1 mg/L vs. M. tuberculosis) [Cynamon 
et al 2004; Teo et al 2006].
An inoculum effect has been noted with NVP LBM-415, 
with 10- to 100-fold increases in inoculum producing 2- to 4-
fold increases in MIC [Fritsche et al 2005]. However, varying 
the incubation environment, pH, or calcium concentration 
and medium supplementation have negligible effects on 
NVP LBM-415 activity [Fritsche et al 2005]. Alterations in 
medium cation content and inoculum (over a range of 102 
to 106 colony-forming units [CFU] per mL) do not have a 
signiﬁ  cant effect on BB-83698 activity [Loﬂ  and et al 2003]. 
Alteration in medium pH does not affect its activity against 
S. pneumoniae but does reduce it against S. aureus and H. 
inﬂ  uenzae. For example, a medium pH of 6 increases S. au-
reus MIC’s about four-fold while the identical pH increases 
the MIC’s of H. inﬂ  uenzae between four- and eight-fold 
[Loﬂ  and et al 2003]. The postantibiotic effect (PAE) duration 
of LBM-415 ranged from 0.3 to 1.4 hours for S. pneumoniae. 
The PAE duration of LBM-415 for S. pneumoniae was not 
affected by strain susceptibility to β-lactams or macrolides 
[Kosowska-Shick et al 2007].
BB-81384, BB-83698, NVP LBM-415, and PDF-611 
exhibit primarily bacteriostatic activity against pneumo-
cocci, staphylococci, mycobacteria, and M. catarrhalis, 
even at medium concentrations up to and exceeding ten-
fold the MIC [Credito et al 2004; Ednie et al 2004; Gross 
et al 2004; Loﬂ  and et al 2004; Fritsche et al 2005; Teo 
et al 2006]. However, bactericidal activity has been noted 
against C. pneumoniae (with NVP PDF 386) [Roblin & 
Hammerschlag 2003], H. inﬂ  uenzae (with BB-83698) [Lo-
ﬂ  and et al 2004] and S. pneumoniae (in 5/16 [31%] strains 
with BB-83698) [Loﬂ  and et al 2003]. NVP LBM-415 is 
active both intra- and extra-cellularly against a variety of 
Legionella species but such activity is bacteriostatic in nature 
[Edelstein et al 2005]. Preliminary data from combination 
studies with NVP LBM-415 demonstrate rare synergy with 
the vast majority of combinations resulting in indifference 
[Fritsche et al 2005].
The in vitro growth curves of S. pneumoniae after exposure 
to linezolid and NVP LBM-415 reveal marked differences in Therapeutics and Clinical Risk Management 2007:3(4) 517
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Table 4  Antibacterial activity of NVP series of peptide deformylase inhibitorsa
 MIC90 (mg/L)
Organism (N)  NVP PDF-386 (VRC 4887)  NVP PDF-713 (LBM-415)  References
Staphylococcus aureus (9865)  1  1  [1–3]
 methicillin-sensitive  (5990)  − 1–2  [3–6]
 methicillin-resistant  (3323)  − 1–4  [3–6]
Coagulase-negative staphylococci (3105)  1  1–2  [1–3]
 methicillin-sensitive  (693)  − 2  [3–6]
 methicillin-resistant  (2143)  − 1–4  [3–6]
β-hemolytic streptococci (963)  − 0.5–1  [2–4,6]
Viridans streptococci (445)  − 0.5–2  [2–4,6]
Streptococcus pneumoniae (2421)  0.5  2  [1–3]
 penicillin-sensitive  (1594)  − 1–2  [3,4,6,7]
 penicillin-intermediate  (533)  − 1  [3,4,6,7]
 penicillin-resistant  (624)  − 0.5–1  [3,4,6,7]
 MDRb (77)    1  [6]
Enterococcus sp. (3758)  2  4  [1–3]
  E. faecalis (2348)  − 4  [3]
 VS  E. faecalis (2262)  − 4  [3,6]
 VR  E. faecalis (118)  − 4  [3]
  E. faecium (914)  − 2  [3]
 VS  E. faecium (393)  − 2  [3,6]
 VR  E. faecium (531)  − 2  [3]
Haemophilus inﬂ  uenzae (3153)  32  4  [1,3]
 beta-lactamase-neg.  (2369)  − 4  [3,4]
 beta-lactamase-pos.  (746)  − 8  [3,4]
Moraxella catarrhalis (341)  0.25 0.5  [1,3,4]
Chlamydia pneumoniae (21)  0.008  − [8]
Mycoplasma pneumoniae (100)  − 0.001  [9]
Legionella sp. (20)  − 16  [10]
  L. pneumophila (50)  − 0.12  [4]
Neisseria sp.    
  N. gonorrhoeae (157)  − 8  [11]
  N. meningitidis (100)  − 2  [11]
Bacteroides sp.    
  B. fragilis (209)  − 0.5  [12]
  B. distasonis (28)  − 0.5  [12]
  B. ovatus (32)  − 0.25  [12]
  B. uniformis (22)  − 0.25  [12]
  B. vulgatus (22)  − 0.5  [12]
Peptostreptococcus sp. (25)  − 1  [12]
Clostridium perfringens (25)  − 2  [12]
Propionibacterium sp. (15)  − 2  [12]
Abbreviations: MIC90 = minimum medium concentration inhibiting the growth of 90% of isolates; MDR = multidrug-resistant (ie, resistant to 3 of penicillin, erythromy-
cin, tetracycline, chloramphenicol, levoﬂ  oxacin, or trimethoprim-sulfamethoxazole);  VS = vancomycin-susceptible;  VR = vancomycin-resistant.
aRange of pooled MIC90 values are shown, where available. Studies were only pooled when each study met all of the following criteria: study used National Committee for 
Clinical Laboratory Standards (NCCLS) methodology, a minimum of 10 isolates were tested for each organism-of-interest, and the test inoculum ranged from 104–106 CFU 
per spot.
1 = Jones and Rhomberg 2003, 2 = Jones et al 2004, 3 = Watters et al 2006, 4 = Fritsche et al 2005, 5 = Credito et al 2004, 6 = Bell et al 2005, 7 = Ednie et al 2004, 8 = Roblin 
& Hammerschlag 2003, 9 = Waites et al 2005, 10 = Edelstein et al 2005, 11 = Jones et al 2005, 12 = Snydman et al 2005.
the time to onset of effect. The inhibitory effect of linezolid was 
already apparent at the 1 hour sampling timepoint while that of 
the PDI was delayed until the 2 hour timepoint [Azoulay-Dupuis 
et al 2004]. Dry-form broth microdilution panels for susceptibility 
testing in NVP LBM-415 clinical trials have been validated 
(99.2% of dry-form MIC results were within ±1 log2 dilution 
of the reference standards with between-day and within-day 
reproducibility being 96.7% and 98.9%, respectively) [Fritsche 
et al 2004a]. Quality control guidelines have also been established 
for this same PDI for disk diffusion and broth microdilution test-
ing, each using 4 strains of American Type Culture Collection 
(ATCC) microorganisms [Anderegg et al 2003, 2004].
Provisional MIC and disk diffusion zone size criteria have 
been published for NVP LBM-415. Sensitive corresponds Therapeutics and Clinical Risk Management 2007:3(4) 519
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to an MIC value of 4 mg/L or less (zone size of 20 mm or 
greater) while resistance is denoted by an MIC value of 16 
mg/L or greater (zone size of 16 mm or less) [Fritsche et al 
2004]. In a collection of 2625 isolates, no strains of staphy-
lococci, S. pneumoniae, other streptococci, or enterococci 
had MIC/zone size values corresponding to resistant. The 
authors thus felt that until resistant isolates of streptococci 
and staphylococci are seen, the only interpretive category for 
these microorganisms should be sensitive. For enterococci 
and H. inﬂ  uenzae, all three interpretive criteria should be 
developed, based on pharmacokinetic/pharmacodynamic and 
MIC population considerations [Fritsche et al 2004].
The development of resistance to PDIs may be a worri-
some issue as these agents enter clinical trials and, eventually, 
the marketplace. Resistant mutants of S. pneumoniae and 
S. aureus were selected at medium concentrations of 2 to 32 
times the MIC and their frequencies were 10–8 to 10–10 and 
2 × 10–6 to 2 × 10–8, respectively [Leeds et al 2004]. Multi-
step resistance selection testing yielded resistant clones with 
fourfold or greater increases in MIC in 11/12 (92%) strains 
of S. pneumoniae after 14–50 daily passages. MICs rose 
from 0.125–1.0 mg/L (parents) to 2–>16.0 mg/L (mutants) 
[Kosowska-Shick et al 2007]. For H. inﬂ  uenzae, two distinct 
mutants were selected, one at medium concentrations of 8 to 
32 times the MIC (frequency of 10–8 to 10–9) and the other at 
medium concentrations of 2 to 4 times the MIC (frequency 
of 6 × 10–8) [Leeds et al 2004]. At a medium concentration 
of 10 times the MIC, resistant mutants of M. bovis BCG 
arose at frequencies of 5 × 10–7 or less [Teo et al 2006]. In a 
global surveillance study conducted between 2002 and 2004, 
one S. aureus isolate was isolated with high-level resistance 
(MIC ≥ 1024 mg/L) to NVP LBM-415. Resistance was due 
to multiple sequence changes in resistance phenotype genes 
(defB [1 nucleotide change] and fmt [3 nucleotide changes]). 
At the time of collection of this isolate, PDIs had not been 
used in humans at all and in vitro and in vivo (animal) 
exposures had been limited to a small number of clinical 
laboratories [Watters et al 2006].
Mutations in the formyl transferase gene (fmt) reduce 
the susceptibilities of S. aureus, H. inﬂ  uenzae, M. bovis 
BCG and E. coli for PDIs. These mutations also produce 
cross-resistance to all PDIs [Margolis et al 2000, Apfel et al 
2001; Leeds et al 2004; Teo et al 2006]. These mutations also 
put these organisms at a disadvantage as their growth rates 
fall, morphologic changes occur (only with H. inﬂ  uenzae), 
and their virulence attenuates compared to wild-type strains 
[Margolis et al 2000; Apfel et al 2001; Leeds et al 2004; 
Teo et al 2006]. Mutations in the defB gene reduce the 
susceptibility of S. pneumoniae to PDIs [Kosowska-Shick 
et al 2007]. In contrast to the fmt gene, mutations of the 
defB gene may not produce cross-resistance across all 
PDIs [Margolis et al 2001]. Another potential mechanism 
of resistance is overexpression of the target enzyme due to 
the def gene ampliﬁ  cation by the microorganism-of-interest 
and/or surrounding microorganisms (“bystanders”) [Apfel 
et al 2001]. This has been noted as a resistance mechanism 
for H. inﬂ  uenzae [Dean et al 2007].
Another potential mechanism of resistance to the PDIs 
involves efﬂ  ux pumps located in the cell membrane/wall 
which act to actively pump antimicrobials out of the cell. 
Inactivation of the AcrAB-TolC efﬂ  ux pump of H. inﬂ  uenzae 
enhances susceptibility to NVP LBM-415 [Dean et al 2005; 
Fritsche et al 2005]. In strains with MICs of 16 mg/L or 
greater, genetic deletion of AcrAB produces hypersuscep-
tible strains and inactivation of AcrAB or TolC signiﬁ  cantly 
enhances susceptibility [Dean et al 2005; Fritsche et al 2005]. 
In contrast to the effect of mutations in the fmt gene, the 
presence of AcrAB or TolC does not alter the growth rate or 
virulence of H. inﬂ  uenzae [Neckerman 2005]. Perhaps the 
presence of this efﬂ  ux pump may account for the modest-
marginal intrinsic activities of PDIs against H. inﬂ  uenzae 
(Tables 1 and 2). In addition, the presence of efﬂ  ux pumps 
also result in reduced susceptibility to the macrolides [Leeds 
et al 2004].
Lastly, mutations in/near the folD gene have a similar 
effect to that of mutations in the fmt gene since both genes 
are necessary to encode the proteins needed for the for-
mylation of methionyl initiator transfer RNA. The folD gene 
encodes the bifunctional enzyme methylene tetrahydrofolate-
dehydrogenase and -cyclohydrolase. Again, bacterial ﬁ  tness 
suffers in acquiring this form of resistance, leading to greatly 
reduced growth rates and virulence [Nilsson et al 2006].
Concerns regarding resistance issues played a signiﬁ  cant 
role in suspension of further development of Ro 66-0376 and 
Ro 66-6976 (Roche).
In vivo (animal) pharmacodynamics
BB-81384 has been evaluated in three animal infection 
models: murine systemic infection (sepsis) model, neutrope-
nic mouse thigh infection model, and murine lung infection 
model [Gross et al 2004]. In the murine sepsis model, an 
inoculum of S. pneumoniae was injected into the peritoneal 
cavity followed one hour later by a single oral dose of anti-
microbial. Five day survival rates (endpoint) were 0, 50, 100, 
100, and 100 percent following BB-81384 10, 30, and 90 
mg/kg, amoxicillin/clavulanate 10 mg/kg, and azithromycin Therapeutics and Clinical Risk Management 2007:3(4) 520
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10 mg/kg, respectively. When BB-81384 was administered 
twice on the day of inoculation (ie, 1 and 5 hours post-
inoculation), the ED50 (dose effective at prolonging survival 
to at least 5 days in 50% of the group) fell from 30 to 20 mg/kg. 
In the neutropenic mouse thigh infection model, an inoculum 
of S. pneumoniae was injected IM into mice rendered neu-
tropenic by intraperitoneal injections of cyclophosphamide 
followed 2 hours later by a single oral dose of antimicrobial. 
BB-81384 30 and 60 mg/kg and amoxicillin/clavulanate 
10 mg/kg produced log10 thigh CFU reductions of 3.8, not 
done and 5.5 at 5 hours post-inoculation, respectively and 2.6, 
3.3, and 5.0 at 24 hours post-inoculation, respectively. In the 
murine lung infection model, an inoculum of S. pneumoniae 
was instilled intranasally followed by 3 days of antimicrobi-
als. BB-81384 100 mg/kg once daily for 3 days produced 
100 percent survival at 3 days but none at 6 days. Three-day 
regimens of 50 mg/kg twice daily and 100 mg/kg twice daily 
both produced 100 percent survival at 3 days and 40 and 67 
percent survival at 6 days, respectively. In addition, the latter 
two regimens reduced the 22 hr log10 lung CFU counts by 
4.3 and 5.6 and the 50 hr log10 CFU counts by 4.5 and 6.0, 
respectively [Gross et al 2004].
Oral and subcutaneous BB-83698 has also been 
evaluated in the neutropenic (and normal) mouse thigh 
infection model. Eight strains of S. pneumoniae were 
investigated, 5 being penicillin-resistant and 3 being 
multi-resistant. Regimens evaluated included single 20 
and 80 mg/kg doses and 24 hour treatment with 5 to 640 
mg/kg/day given at dosing intervals of 3, 6, 12, and 24 
hours. Based on thigh CFU values, BB-83698 was bacte-
ricidal and exhibited in vivo post-antibiotic effect (PAE) 
values of 6 to 13 hours. The pharmacodynamic parameter 
which best correlated with efficacy in neutropenic mice 
was the ratio of 24 hour area under the plasma concentra-
tion versus time curve (AUC)/MIC (r2 = 0.91). Efficacy 
was predicted when AUC/MIC was 133 or higher. The 
ratio of peak plasma concentration (Cmax)/MIC and pro-
portion of the dosing interval where plasma concentra-
tion exceeded the MIC had lower r2 values of 0.50 and 
0.60, respectively. The dosing interval had no effect on 
the total dose needed to exert a bacteriostatic effect in 
neutropenic mice. These data supported evaluation of a 
once-daily dosing regimen for the treatment of pneumo-
coccal infections [Craig 2001].
In a murine model of pneumococcal pneumonia (MICs 
of the 4 test strains were 0.06 to 0.25 mg/L), BB-83698 80 
mg/kg twice daily SC or 160 mg/kg once daily SC protected 
70 to 100 percent of animals at 10 days post-inoculation. 
Bacterial burden in the bloodstream and lungs both fell in a 
dose-dependent fashion [Azoulay-Dupuis et al 2004]. After 
a single 80 mg/kg SC dose, mean serum and lung tissue 
Cmax/MIC ratios were 238 and 1032 to 1, respectively. Cor-
responding mean 24 hour AUC/MIC ratios were 957 and 
3823 to 1 [Azoulay-Dupuis et al 2004].
BB-3497 (IV, oral) was evaluated in the murine sepsis 
model using  S. aureus Smith. The ED50’s were 7 mg/kg (IV) 
and 8 mg/kg (oral). With a methicillin-resistant S. aureus test 
strain, the ED50 for oral drug rose to 14 mg/kg [Clements et al 
2001]. NVP LBM-415 was evaluated in a M. pneumoniae 
pneumonia model in mice. Drug was dosed as 50 mg/kg 
once daily SC. As compared to untreated mice, drug-treated 
mice exhibited signiﬁ  cant reductions in bronchoalveolar 
lavage (BAL) ﬂ  uid M. pneumoniae CFU counts on days 
6 and 13 on treatment and lung histopathology scores on 
days 3, 6, and 13 on treatment and 7 days after treatment. 
Airway obstruction fell signiﬁ  cantly in active-treated mice 
on days 1, 3, and 6 on treatment and 7 days after treatment 
while airway hyperresponsiveness fell only on day 3 on 
treatment. Signiﬁ  cant reductions were found in the BAL 
ﬂ  uid concentrations of most, but not all, cytokines and 
chemokines (eg, tumor necrosis factor alpha, interferon 
gamma, interleukins −6 and −12, functional interleukin −8, 
monocyte chemotactic protein −1, macrophage inﬂ  amma-
tory protein 1α, monokine induced by interferon-gamma, 
and interferon-inducible protein 10) in active-treated mice 
[Fonseca-Aten et al 2005].
VRC 3375 was evaluated in the murine sepsis model 
(S. aureus Smith). The ED50 values were 32 mg/kg (IV), 
17 mg/kg (SC), and 21 mg/kg (oral) [Chen et al 2004]. In 
this same model, the ED50 for VRC 4307 was 17.9 mg/kg 
(SC) (no efﬁ  cacy was seen with oral VRC 4307, even at 30 
mg/kg) [Hackbarth et al 2002]. For VRC 4232, the ED50 
was 29.7 mg/kg (SC) [Hackbarth et al 2002].
The acute toxicology has been described for one PDI, 
VRC 3375. The LD50 (lethal dose for 50% of mice) was 447 
mg/kg (IV), with 3 deaths occurring immediately post-injec-
tion. No deaths were reported after SC and oral dosing. Day 
8 necropsy results were unremarkable except in 3 mice in 
the 500 mg/kg SC groups (all had dark red skin plaques at 
the injection site) [Chen et al 2004].
Animal pharmacokinetics
The BB series of PDIs are quantiﬁ  ed in biological samples 
using high performance liquid chromatography (HPLC) 
with tandem mass spectrometry (MS) [Clements et al 
2001; Azoulay-Dupuis et al 2004; Gross et al 2004; Therapeutics and Clinical Risk Management 2007:3(4) 521
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Table 5 Mean pharmacokinetic parameters for selected peptide deformylase inhibitors in mice and rats
Reference/     Cmax T max  AUC  CL  t 1/2   Vss F
species Compound  Regimen  (mg/L)  (min.)  (mg/L•h) (mL/min/kg) (h)  (L/kg) (%)
[Azoulay-Dupuis  BB-83698  80 mg/kg SC  14.3a 60  57.4a,c –  2.5a –  –
et al 2004]/mice    × 1 dose  61.9b 60  229.4b,c –  2.6b –  –
[Ramanathan-  BB-83698  10 mg/kg IV  6.3  –  3.8  44.4  1.0  2.0  –
Girish et al 2004]/    × 1 dose
mice  
    50 mg/kg IV  44.6  –  55.1  15.1  2.6  2.6  –
   × 1 dose
[Craig 2001]/  BB-83698  20 and 80 mg/kg  –  –  –  –  1.6–1.7  –  50
neutropenic mice    SC and PO 
   × 1 dose each
[Gross et al 2004]/  BB-81384  10 mg/kg IV  15.1  –  6.5d 25  2.2  1.6  –
mice   × 1 dose
    10 mg/kg oral  1.6  –  3.6d –  3.1  –  55
   × 1 dose
    50 mg/kg oral  21.3  –  28.6d –  3.7  –  88
   × 1 dose
[Clements et al  BB-3497  100 mg/kg oral  24.0  –  34e –  –  –  –
2001]/rats   × 1 dose 
[Chen et al 2004a]/  VRC 3375  100 mg/kg IV  –  –  –  –  0.25  –  –
mice   × 1 dose
    100 mg/kg SC  66  20  –  –  0.25  –  –
   × 1 dose
    100 mg/kg PO  43  10  –  –  0.25  –  64
   × 1 dose
[Hackbarth et al  VRC 4232  13 mg/kg IV  5580  –  –  –  1.1  –  –
2002]/mice   × 1 dose
    13 mg/kg oral  167  –  –  –  –  –  3.2
   × 1 dose
  VRC 4307  3.7 mg/kg IV  1720  –  –  –  0.1  –  –
   × 1 dose
    3.7 mg/kg oral  1.5  15  –  –  –  –  0.1
   × 1 dose
[Teo et al 2006]/  PDF-611  1 mg/kg IV  604f –  254g 65.8  0.5  3.0  –
mice   × 1 dose
    5 mg/kg oral  194f 15  566g –  3.7  – 45
   × 1 dose             
Abbreviations: Cmax = peak plasma concentration, Tmax = time to Cmax, AUC = area under the plasma concentration-versus-time curve, CL = total body clearance, t 1/2 = 
terminal disposition half-life, Vss = volume of distribution at steady-state, F = oral bioavailability.
aserum.
blung.
cOver 10 hrs. post-dose.
dOver 5 hrs. post-dose.
eOver 24 hrs. post-dose.
fng/mL.
gng/mL•h.
Ramanathan-Girish et al 2004]. The VRC series of 
PDIs are also quantitated using HPLC with tandem MS 
as well as HPLC with ultraviolet detection [Hackbarth 
et al 2002, Chen et al 2004a; Teo et al 2006]. Table 5 
illustrates the mean pharmacokinetic parameters of a 
variety of peptide deformylase inhibitors in mice and rats 
[Clements et al 2001; Craig 2001; Hackbarth et al 2002; 
Azoulay-Dupuis et al 2004; Chen et al 2004a; Gross et al 
2004; Ramanathan-Girish et al 2004; Teo et al 2006].
Absorption
BB-83698 is reasonably well-absorbed by the oral route, 
with a mean bioavailability of 50 percent in neutropenic 
mice [Craig 2001]. Absorption proceeds rapidly after oral Therapeutics and Clinical Risk Management 2007:3(4) 522
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administration, with a mean time to peak plasma concentra-
tion (Tmax) of about 1 hour [Azoulay-Dupuis et al 2004]. 
BB-81384 is also reasonably well-absorbed after oral 
administration, with mean bioavailabilities of 55 percent (10 
mg/kg orally) and 88 percent (50 mg/kg orally) [Gross et al 
2004]. Of the VRC series of compounds, only VRC 3375 
is reasonably well-absorbed, with a mean bioavailability 
of 64 percent and Tmax of 0.167 to 0.33 hours [Chen et al 
2004a]. The mean oral bioavailabilities of VRC 4232 and 
VRC 4307 are 3.2 and 0.1 percent, respectively [Hackbarth 
et al 2002]. Absorption proceeds rapidly with VRC 4307, 
the mean Tmax being 0.25 hours [Hackbarth et al 2002]. The 
antimycobacterial PDF-611 is also reasonably well-absorbed, 
with a mean bioavailability of 45 percent and Tmax of 0.25 
h [Teo et al 2006].
For NVP LBM-415, the mean Tmax after oral dosing was 
the same in rats and mice (0.5 hr) [Chen et al 2004a]. Oral 
bioavailability averaged 65% in mice but ranged from 21 to 
94% in rats over a dose range of 12 to 436 mg/kg (latter being 
an effect of saturable metabolism, not altered bioavailability) 
[Chen et al 2004a].
Distribution
For VRC 3375 in mice, concentrations in heart, kidney, and 
lung tissue exceeded those in serum while those in muscle 
and serum were comparable at 3 minutes following IV dosing 
of 100 mg/kg [Chen et al 2004a].
For BB-81384, after a single 10 mg/kg oral dose, lung 
tissue and plasma concentrations were approximately equiva-
lent over a ﬁ  ve hour period following dosing while thigh 
muscle concentrations were approximately one-third those in 
plasma over the same time period. Peak concentrations were 
achieved within 20 minutes in all 3 compartments [Gross 
et al 2004]. For BB-83698, after an 80 mg/kg SC dose, lung 
tissue concentrations exceeded those of serum by approxi-
mately four-fold, whether measured by Cmax or AUC (Table 
5) [Azoulay-Dupuis et al 2004]. For NVP LBM-415, lung 
tissue concentrations were double those in plasma after both 
oral and IV dosing in mice [Chen et al 2004a].
Metabolism and excretion
VRC 4232/4307 are rapidly metabolized in mouse and 
rat hepatic microsomes, in contrast to their metabolism 
in human microsomes [Hackbarth et al 2002]. For VRC 
4232, metabolism by mouse, rat, and human microsomes 
is extensive, with hydroxylation predominating but also 
oxidation, hydrolysis, and reduction, all followed by 
glucuronidation [Hackbarth et al 2002]. As all metabolites 
exhibit an altered hydroxamic acid moiety, all should be 
microbiologically inactive [Hackbarth et al 2002]. The pat-
tern of metabolites varied with species and with the model 
used (ie, in vivo animal versus in vitro liver microsomes). 
Thus, the patterns of the three major metabolites were 
different for the in vivo mouse, mouse liver microsome, 
rat liver microsome and human liver microsome models. 
In human liver microsomes, the three major metabolic 
products (in descending order of amount) were the prod-
uct of proline hydroxylation and hydrolysis, the product 
of hydrolysis alone, and the glucuronide conjugate of the 
parent compound [Hackbarth et al 2002].
Multiple-dose studies with BB-83698 have been conducted 
in rats and dogs at 3 dose levels (10, 22, and 50 mg/kg IV once 
daily × 28 days). In rats, mean day 1 peak plasma concentra-
tions rose 2.5-fold (expected 2.2-fold from 10 to 22 mg/kg) and 
4.9-fold (expected 5-fold from 10 to 50 mg/kg) in males with 
corresponding values in females of 2.6- and 6.6-fold. Mean day 
1 AUC rose 2.2-fold and 6.6-fold in males and 3.1-fold and 
8.8-fold in females. Mean day 28 peak plasma concentrations 
rose 3.4-fold and 3.3-fold in males and 2.6-fold and 4.2-fold in 
females. Mean day 28 AUC rose 3.4-fold and 14.4-fold in males 
and 2.7-fold and 9.4-fold in females. In rats, BB-83698 exhibited 
non-linear pharmacokinetics in both genders, especially at the 
higher 50 mg/kg dose and when quantitated using AUC data 
(ie, the rise in AUC was disproportionately high compared to 
the rise in dose). In the dog, non-linear pharmacokinetics were 
also noted in both genders. However, this was apparent with 
both Cmax and AUC data and with the 22 and 50 mg/kg dose. 
In the case of the dog, the rises in Cmax and AUC were dispro-
portionately low compared to the rises in dose (dog data not 
shown) [Ramanathan-Girish et al 2004].
From day 1 to day 28, the mean degrees of accumulation 
as measured by change in Cmax were 1.2-, 1.6-, and 0.8-fold 
in males and 1.5-, 1.6-, and 1.0-fold in females (with doses 
of 10, 22, and 50 mg/kg, respectively). The corresponding 
degrees of accumulation as measured by change in AUC 
were 0.8-, 1.4-, and 1.9-fold in males and 0.8-, 0.7-, and 
0.8- fold in females. In both rats and dogs, accumulation 
over 28 days occurred to a minor extent, if at all, whether 
quantitated using Cmax or AUC data (dog data not shown) 
[Ramanathan-Girish et al 2004].
After IV administration of NVP LBM-415, the mean total 
body clearances in mice and rats were 5.19 and 1.27 L/h/kg, 
respectively [Chen et al 2004]. Peak plasma concentration 
and AUC did not rise in proportion to dose in rats due to 
(presumed) saturable metabolism [Chen et al 2004]. In the 
ﬁ  rst 24 hours after IV drug administration, mean urinary Therapeutics and Clinical Risk Management 2007:3(4) 523
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excretion of parent compound was 19 percent of the dose in 
mice and 48 percent of the dose in rats [Chen et al 2004a]. 
Mean biliary excretion in the ﬁ  rst 7 hours after IV dosing 
was 23 percent in rats [Chen et al 2004a].
Human pharmacokinetics
Few published data exist regarding the pharmacokinetics 
of PDIs in humans. One published phase I clinical trial 
evaluated the pharmacokinetics and tolerability of ascend-
ing single intravenous doses (10, 25, 50, 100, 200, 325, 
400, 475 mg) of BB-83698 in healthy male volunteers. 
All doses were administered over 15 minutes. No signiﬁ  -
cant adverse events (AEs) occurred at any dose level. The 
overall mean ± SD clearance was 238 ± 130 mL/min, with 
CL’s ranging from 189 mL/min (475 mg) to 521 mL/min 
(10 mg). Linearity was evident with Cmax and AUC data, 
although these data did appear to deviate somewhat at the 
lowest and highest doses. Further studies are necessary to 
resolve this issue. However, Vdss and t 1/2 did vary signiﬁ  -
cantly with dose (ranging from 57–106 L and 4.8–16.7 h, 
respectively). Plasma protein binding ranged from 78 to 
82 percent [Ramanathan-Girish et al 2004].
Similar single and multiple dose pharmacokinetic stud-
ies have also been conducted with oral NVP LBM-415. 
After single oral doses of 100, 250, 500, 1000, 2000, and 
3000 mg, the median Tmax was 1 hr or less in all dosing 
groups. Linearity was noted for dose-normalized 12-h AUC 
data. The mean t 1/2 ranged from 2 to 3 h except in the 
2000 mg group (where the value was 4.2 h). When a 1000 
mg dose was taken immediately after ﬁ  nishing breakfast, 
as compared to ingestion in the fasting state, the Tmax was 
prolonged (median rose from 0.5 to 2 h) and Cmax fell (mean 
fell from 15.5 to 6.7 mg/L) but the AUC was statistically 
unchanged. After multiple oral dosing (250, 500, and 1000 
mg twice daily for 11 d), no accumulation was noted and 
steady-state was achieved after one day of dosing. These 
data supported the evaluation of a twice daily regimen in 
clinical trials [Jain et al 2005].
Timelines for development 
of BB-83698 and NVP LBM-415
BB-83698
In October 2002, BB-83698 (developed by British Biotech in 
collaboration with Genesoft) entered phase I studies in 
humans. Although dose-limiting central nervous system 
adverse events (AEs) such as trauma, unsteady gait and 
seizures had occurred in dogs, no significant AEs were 
seen in humans. The probable therapeutic dose was 
judged to be 475 mg, based on an AUC/MIC value of 
184 (assuming, in turn, an MIC for S. pneumoniae of 
0.25 mg/L). Development was terminated for unknown 
reasons when British Biotech became Vernalis. Oscient 
has now purchased this compound and one must wait to 
see the drug’s ultimate fate.
NVP LBM-415
In October 2003, NVP LBM-415 (developed by Vicuron 
in collaboration with Novartis) entered phase I studies in 
humans. Multiple dose pharmacokinetic studies used dos-
age regimens of 250 and 500 mg twice daily. No signiﬁ  cant 
AEs were seen after administration of single doses up to and 
including 3g. However, Novartis and Vicuron discontinued 
its development in April 2004. Vicuron was purchased by 
Pﬁ  zer in June 2005. However, Novartis appears to be still 
pursuing PDI’s, most recently the antimycobacterial NVP 
PDF-611 (LBK611).
Conclusion
The relatively rapid development of microbial resistance after 
the entry of every new antimicrobial into the marketplace 
necessitates a constant supply of new agents to maintain ef-
fective pharmacotherapy. Despite extensive efforts to identify 
novel lead compounds from molecular targets, only the peptide 
deformylase inhibitors (PDIs) have shown any real promise, 
with some advancing to phase I human trials. Bacterial peptide 
deformylase, which catalyzes the removal of the N-formyl 
group from N-terminal methionine following translation, is 
essential for bacterial protein synthesis, growth, and survival. 
The majority of PDIs are pseudopeptide hydroxamic acids and 
two of these (IV BB-83698 and oral NVP LBM-415) entered 
phase I human trials. However, agents to the present have 
suffered from major potential liabilities. Their in vitro activity 
has been limited to gram-positive aerobes and some anaerobes 
and has been quite modest against the majority of such species 
(MIC90 values ranging from 1–8 mg/L). They have exerted 
bacteriostatic, not bacteriocidal, activity, thus reducing their 
potential usefulness in the management of serious infections 
in the immunocompromised. The relative ease with which 
microorganisms have been able to develop resistance and the 
multiple available mechanisms of resistance (mutations in fmt, 
defB, folD genes; AcrAB/TolC efﬂ  ux pump; overexpression 
of peptide deformylase) are worrisome. These could portend 
a short timespan of efﬁ  cacy after marketing. Despite these 
current liabilities, further pursuit of more potent and broader 
spectrum PDIs which are less susceptible to bacterial mecha-
nisms of resistance is still warranted.Therapeutics and Clinical Risk Management 2007:3(4) 524
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Note in proof
The recent discovery of a peptide deformylase homologue (mito-
chondrial PDF or mPDF) in humans has raised major objections 
to using PDF as a target of antimicrobial drugs. Indeed, mPDF 
is functional, displaying PDF activity in the human mitochon-
drion; is involved in the same essential pathway as in bacteria; 
is inhibited in vitro and in vivo by actinonin (see above); and, 
when inhibited, produces an antiproliferative effect triggered 
by mitochondrial dysfunction leading to cell death. Fortunately, 
PDF exists in 3 forms: PDF1B and PDF2 (both are bacterial 
PDFs) and PDF1A (human mPDF). Thus, the search is now on 
for compounds that selectively inhibit PDFs 1B and 2 and have 
no effect on PDF1A. At least one compound with this spectrum 
of enzyme activity is now known: 2-(5-bromo-1H-indol-3-yl)-
N-hydroxyacetamide [Boularot et al 2007].
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